(Q35102493)

6 August 2017

1 reference

title

Treatment of the psychotic patient who is violent (English)

1 reference

6 August 2017

1 reference

1 reference

Peter F Buckley

1

1 reference

6 August 2017

Stephen G Noffsinger

2

1 reference

6 August 2017

Douglas A Smith

3

1 reference

6 August 2017

Debra R Hrouda

4

1 reference

6 August 2017

James L Knoll

5

1 reference

6 August 2017

publication date

1 March 2003

1 reference

Psychiatric Clinics of North America

6 August 2017

published in

1 reference

6 August 2017

volume

26

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

231-272

1 reference

Understanding causal paths between mental illness and violence.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

New evidence on the violence risk posed by people with mental illness: on the importance of specifying the timing and the targets of violence.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Mental disorder and violence. A special (high security) hospital study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Violence by People Discharged From Acute Psychiatric Inpatient Facilities and by Others in the Same Neighborhoods

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Serious criminal offending and mental disorder. Case linkage study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

A prospective study of violence by psychiatric patients after hospital discharge

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Schizophrenia and assaultive behaviour: the role of alcohol and drug abuse

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Aggression in humans correlates with cerebrospinal fluid amine metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

A replication study of violent and nonviolent subjects: cerebrospinal fluid metabolites of serotonin and dopamine are predicted by plasma essential fatty acids.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Ipsapirone neuroendocrine challenge: relationship to aggression as measured in the human laboratory

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Predicting compliance with command hallucinations.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Command hallucinations and the prediction of dangerousness

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Women who kill their parents

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Violence and delusions: data from the MacArthur Violence Risk Assessment Study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Men with schizophrenia who behave violently: the usefulness of an early- versus late-start offender typology.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Psychiatric impairment, social contact, and violent behavior: evidence from a study of outpatient-committed persons with severe mental disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Risk reconsidered: targets of violence in the social networks of people with serious psychiatric disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Prospective study into factors associated with aggressive incidents in psychiatric acute admission wards.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Violence and aggression in psychiatric units.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Predictors of violence in civilly committed acute psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Violence in inpatients with schizophrenia: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Criminality and aggression among psychotic in-patients: frequency and clinical correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Risk appraisal and management of violent behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Legal issues in treating perpetrators and victims of violence

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Clinical use of high-dose neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Effect of clozapine on physical and verbal aggression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Management of treatment resistance in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Clozapine-associated reduction in arrest rates of psychotic patients with criminal histories

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Effect of Risperidone on Hostility in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Treatment-refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

An open trial of olanzapine in patients with treatment-refractory psychoses.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Ziprasidone: pharmacology, clinical progress and therapeutic promise

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

1 reference

7 January 2021

Psychopharmacologic treatment of pathologic aggression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Carbamazepine maintenance treatment in outpatient schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Advocacy, recovery, and the challenges of consumerism for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

The right to refuse psychiatric treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Tests of competency to consent to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Assessing patients' capacities to consent to treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

The right to refuse treatment with antipsychotic medications: retrospect and prospect

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Why do schizophrenic patients refuse to take their drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Psychopathologic domains and insight in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Randomised controlled trial of compliance therapy. 18-month follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Psychiatric advance directives: an alternative to coercive treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

A survey on use of advance directives for mental health treatment in Oregon

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

The use of advance directives by persons with serious mental illness for psychiatric treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Mandated community treatment: beyond outpatient commitment

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Advance directives for mental health treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Coerced treatment in the community

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

A randomized controlled trial of outpatient commitment in North Carolina.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Assessing the New York City involuntary outpatient commitment pilot program.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Management of threats of violence under California's duty-to-protect statute

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Relation between negligent adverse events and the outcomes of medical-malpractice litigation.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Comparing outcomes of major models of police responses to mental health emergencies.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

A specialized crisis response site as a core element of police-based diversion programs.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Persons with severe mental illness in jails and prisons: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

Dangerousness: a paradigm for exploring some issues in law and psychology

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900029-1

7 January 2021

10.1016/S0193-953X(02)00029-1

Identifiers

DOI

1 reference

6 August 2017

1 reference